Nordic Drugs believe in fair, sustainable and high-quality drug development, production and distribution.
Nordic Drugs will attend BIO-Europe in Hamburg, November 11-13.
Nordic Drugs will attend Bio-Europe in Copenhagen, November 5-7.
Nordic Drugs will attend BIO-Europe in Berlin, November 6-8.
During 24-26 October, Nordic Drugs will attend CPHI in Frankfurt.
Nordic Drugs strengthen its position in the addiction therapy area by launching Buprenorphine G.L. Pharma, 2 mg and 8 mg sublingual tablets in Sweden.
Nordic Drugs will attend BIO Europe in Cologne, November 7-9. You are most welcome to contact us for a meeting during these days.
We are happy to announce the signing of two new products from our long-term partner in generics, G.L. Pharma. This recent signing means that during 2016, we have signed four new products from G.L. Pharma to be introduced in 2017.
During 14-15 September, Nordic Drugs will attend Nordic Life Science Days in Stockholm. Be sure to contact us if you will be in Stockholm and want to set up a meeting.
As of March this year, Nordic Drugs has launched Hidrasec (racecadotril) as an OTC product in Denmark. Indication is acute diarrhea in adults. Unlike other registered pharmaceutical products used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect - it reduces the secretion of water and electrolytes into the intestine.
This is the first product where Nordic Drugs has carried out an OTC-switch, but not the last. Hidrasec is licensed from the French company Bioprojet Pharma.
During 4-6 April, Nordic Drugs will attend BIO-Europe in Stockholm. Be sure to contact us if you will be in Stockholm and want to set up a meeting.
Nordic Drugs has launched Laxido Junior as an addition to our already existing business with Laxido adult formulation in Sweden. At Nordic Drugs, we see this as a natural expansion of the co-operation between Nordic Drugs and Galen (Northern Ireland) regarding generic products in the Nordic area.
Nordic Drugs will attend the Nordic Life Science Days in September. Be sure to contact us if you are in Stockholm and want to set up a meeting.
With the mission to find new interesting products suitable for launch in the Nordic countries, Nordic Drugs will attend BIO-Europe in November. Be sure to contact us if you are in Frankfurt and want to set up a meeting.
After launching Hidrasec as well as securing yet one more product launch (around end of 2014, more information will follow) we will take a well-deserved break and enjoy our summer vacation. We wish you all a nice summer and look forward to getting back in touch in August!
As an addition to our already strong portfolio within gastroenterology, Nordic Drugs will launch Hidrasec® (racecadotril) in the Nordic countries. Indication is acute diarrhea in adults and children (older than three months). Unlike other products used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect - it reduces the secretion of water and electrolytes into the intestine.
Hidrasec is licensed from the French company Bioprojet Pharma, it is marketed today in more than 30 countries, mostly through licensees.
Nordic Drugs will attend BIO-Europe in November. Be sure to contact us if you are in Vienna and want to set up a meeting.
European Commission approved reinstatement of aprotinin/Trasylol® marketing authorisation in European Union.
The European Commission has approved the reinstatement of aprotinin marketing authorisations in European Union. This confirms the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) from May 2013, recommending these reinstatements. The recommendation took into account a full and independent review of the benefits and risks of aprotinin, which found that the results of the study, on which the suspension of aprotinin was based, were unreliable.
Since 2007 Nordic has performed limited access programmes and is now looking forward to placing aprotinin in European markets (including Scandinavia) according to national regulatory timelines.
Since July 1, 2013, Nordic Drugs is responsible distributor of Proibs® – a product for treatment of IBS (Irritable Bowel Syndrome) – in the Nordic countries.
Proibs was developed, and until now marketed in Sweden, by Swedish company Calmino group. Proibs is already available at all pharmacy chains in Sweden and for Nordic Drugs this is an excellent addition to our important gastroenterology product portfolio.
We look forward to continue the launch of the product in Sweden and to introduce the product in Denmark, Norway and Finland in the near future.
Gaviscon® from Nordic Drugs to be the first non-prescription pharmaceutical product on the market by Snabboteket AB.
The Swedish company, Snabboteket AB offers non-prescription products in smaller packs for immediate consumption using new sales channels such as trains, airports, hotels and other places where people are “on the go”. Nordic Drugs well-established product Gaviscon, for treatment of indigestion and heartburn, will be the first non-prescription pharmaceutical product included in the product portfolio of Snabboteket and will be available in a pack of two chewable tablets.
Pernilla Agardh, Marketing Manager OTC at Nordic Drugs comments:
“I see this as an excellent example of Nordic Drugs ability to adopt to new market conditions following the deregulation of the pharmacy market in Sweden some years ago.
It also shows Nordic Drugs commitment to mature products in our portfolio, long-term is not just an empty phrase for us and we constantly seek to improve ourselves when it comes to life-cycle management.”
Following the successful launch of Oxycodone Lannacher, Nordic Drugs recently signed licensing agreements for two new products to be launched during 2013. We will disclose further information regarding these products at a later stage. Next chance to meet us at a partnering event will be at BIO-Europe in Barcelona 11th-13th of March, be sure to schedule a meeting with us there if you have products of interest for the Nordic countries.
Nordic Drugs has recently launched Oxycodone controlled-release formulation as an addition to our already existing Pain management portfolio. This launch is an example of further strengthening of the successful cooperation between Nordic Drugs and G.L. Pharma regarding generic products in the Nordic area.
From a product perspective we held a very successful European Teysuno launch event at World of GI Cancer Congress Barcelona end of June. We are all very excited about Teysuno, our first product in the oncology portfolio, and the possibility to offer such a high profile product to suffering patients in need.
From a business development perspective, we are about to sign agreements for at least three new products. At least one of these products will be launched already in 2012. This means that Nordic Drugs has a solid base for future growth in coming years.
Nordic Drugs awarded Life Science company of the year 2011!
At Malmö Business Gala 2012, held February 27th, Nordic Drugs won the award Life Science company of the year 2011. Nordic Drugs was awarded the prize in competition from two other strong nominees and the motivation from the jury was as follows:
“Life Science company of the year prize is awarded a company that has had a strong positive development, looking at turnover as well as number of employees, since the start 17 years ago. Today, this company is a well-known and successful pharmaceutical company that cover all Nordic countries with its products. These products all have in common that they increase the possibility for people to live satisfactory and active lives. “
The next opportunity to meet Nordic Drugs at a partnering event will be at BIO-Europe in Amsterdam (March 19-21). Be sure to contact us if you are in Amsterdam and want to set up a meeting.
With the launch of Teysuno™ (advanced gastric cancer) Nordic Drugs will further strengthen the position as one of the leading speciality pharma companies in the Nordic region. The product will be launched early 2012 in Sweden, Denmark, Finland and Norway.
Teysuno will be the first product in the oncology portfolio currently being set up by Nordic Drugs, several potential additions to this portfolio are currently being evaluated.
During the summer 2011, Nordic Group BV and Taiho Pharmaceutical Co. entered into a development and commercialization agreement for Teysuno covering the EU and other selected European countries.
Clinical development of Spanidin®, an immunosuppressive agent for granulomatosis with polyangiitis, GPA, (formerly known as Wegener´s) has now started in Sweden. A total of 30 centers across Europe will be involved, six of them are Swedish.
Anders Löfgren, Managing Director of Nordic Drugs, comments:
“Entering into clinical development with a product like Spanidin is a landmark for Nordic Drugs and further strengthens our position as a leading speciality pharma company in the Nordic region. We are proud to be part of the development of this product which will help severely sick patients. I would also like to stress the fact that 6 out of 30 involved research centers across Europe are located in Sweden.”
GPA is an incurable form of vasculitis (inflammation of blood vessels) that affects the nose, lungs, kidneys and other organs.
Nordic Drugs has been nominated in the category Life Science company of the year at Malmo Business Gala 2012. The gala will take place in February 2012 and we will of course let you know the result.
Nordic Drugs will attend BIO-Europe Milan in March. Be sure to contact us if you are in Milan and want to set up a meeting.
The Nordic Pharma Group announces a strategic collaboration with Nippon Kayaku on Spanidin® (gusperimus) in selected territories outside Japan, including Scandinavia.
Nippon Kayaku (NK) and the Nordic Pharma Group (Nordic) have signed a licensing agreement under which NK grants exclusive rights to NORDIC for the development and commercialisation of Spanidin in selected territories outside of Japan, including Scandinavia.
Spanidin is an immunosuppressive agent developed and commercialised in Japan by NK in acute and accelerated rejection crisis after renal transplantation. The product has also obtained promising results and orphan medicinal product status in Europe for the treatment of Wegener´s Granulomatosis (WG). Spanidin has the potential to offer a treatment for relapsing WG patients, who currently have no approved drug to cure their disease.
With this new agreement, Nordic is actively pursuing its strategy to bring innovative drugs to the market in specialized therapeutic areas that have specific, unmet medical needs. As part of Nordic Pharma Group, Nordic Drugs will take Spanidin to market in Sweden, Denmark, Finland and Norway.
During January 10-13, Nordic Drugs will attend The Finnish Medical Convention 2011 in Helsinki. Don´t hesitate to contact us at our booth if you want to learn more about our operations in Finland and/or the other Nordic countries.
Nordic Drugs has signed a distribution agreement with the Japanese pharmaceutical company Seikagaku Corporation regarding marketing of Artz®/Artzal® in Sweden, Denmark and Finland.
Artz/Artzal is a well-known product used for the treatment of pain in osteoarthritis of the knee and will be a logical addition to our Pain & Inflammation portfolio. The product was originally developed by Seikagaku Corporation and previous MA-holder in the territory was AstraZeneca.
The next opportunity to meet representatives from Nordic Drugs at a partnering event will be at BIO-Europe Munich in November.